2 results
Approved WMOCompleted
to assess patient's overall preference for the two inhaler devices in COPD patients after 2 weeks of dialy practice.
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…